doi: 10.1007/s00204-023-03562-9 12 JuchnowiczDDzikowskiMRogJWaszkiewiczNZalewskaAMaciejczykMet al
Tested for quality assurance Each batch of our glutathione is tested for heavy metals and other harmful substances by a third-party licensed and accredited lab using the most advanced methods of detection
During the early stages of its development, BPC 157 primarily garnered attention for its gastroprotective and ulcer-healing properties
Cholelithiasis (gallstones) was reported at low rates in the Phase 2 trial Incidence was slightly higher in higher-dose groups, though absolute numbers were small This observation is not unique to retatrutide semaglutide and tirzepatide trials also reported gallbladder events Cardiovascular Observations Heart rate changes were documented in clinical trial participants: Small mean increases in heart rate (2-4 bpm) were observed in active treatment groups This is consistent with GLP-1 agonist class effects semaglutide and tirzepatide produce similar heart rate increases No increased rate of major adverse cardiovascular events (MACE) was observed in Phase 2 TRIUMPH-4 is specifically designed to evaluate cardiovascular outcomes at scale Injection Site Reactions As a subcutaneous injectable, injection site reactions were reported: Injection site erythema, pain, and pruritus were documented at low rates Most injection site events were Grade 1 (mild) No injection site reactions led to treatment discontinuation in published data How Retatrutide Adverse Events Compare to Other GLP-1 Compounds Comparing adverse event profiles across different trials has significant limitations patient populations, dose ranges, and endpoint definitions vary
Although this scenario does present an added degree of clinical complexity, it is important to consider the possible co-occurrence of two disease processes and the role of interaction between the two
